Barclays
ARIA

Barclays’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Barclays’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-17,361
Closed -$216K – 7226
2016
Q4 		$216K Buy
17,361
+5,120
+42% +$61.7K ﹤0.01% 4160
2016
Q3 		$167K Buy
12,241
+6,436
+111% +$64.6K ﹤0.01% 4122
2016
Q2 		$43K Sell
5,805
-19,617
-77% -$147K ﹤0.01% 4918
2016
Q1 		$153K Sell
25,422
-218,333
-90% -$1.22M ﹤0.01% 4046
2015
Q4 		$1.46M Buy
243,755
+183,523
+305% +$1.2M ﹤0.01% 2277
2015
Q3 		$301K Buy
60,232
+49,699
+472% +$383K ﹤0.01% 3797
2015
Q2 		$84K Sell
10,533
-23,254
-69% -$206K ﹤0.01% 4788
2015
Q1 		$270K Sell
33,787
-96,776
-74% -$715K ﹤0.01% 4116
2014
Q4 		$783K Buy
130,563
+46,261
+55% +$289K ﹤0.01% 3427
2014
Q3 		$422K Sell
84,302
-3,038
-3% -$17.7K ﹤0.01% 4086
2014
Q2 		$525K Sell
87,340
-37,610
-30% -$259K ﹤0.01% 3935
2014
Q1 		$999K Sell
124,950
-1,801,931
-94% -$14M ﹤0.01% 3237
2013
Q4 		$11.6M Buy
1,926,881
+1,727,814
+868% +$9.33M 0.01% 1144
2013
Q3 		$3.58M Buy
199,067
+106,152
+114% +$2.06M ﹤0.01% 1990
2013
Q2 		$1.63M Buy
+92,915
New +$1.65M ﹤0.01% 2772

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Barclays's ARIA Position: Q1 2017 in Review

Barclays sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 17,361 shares — an estimated $216K sold.

Barclays first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $11.6M in Q4 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Barclays reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Barclays sold 17,361 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $216K.
  • Barclays first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Barclays's Ariad Pharmaceuticals Inc position peaked at $11.6M in Q4 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Barclays's 13F filing for Q1 2017, filed 15 May 2017.